Correlation Between Intron 4 Polymorphism of the Endothelial Nitric Oxide Synthase Gene and Cardiovascular Risk with the Numbers of Circulating Endothelial Progenitor Cells in Healthy Subjects
In the present study, we investigated the relationship between an important 27 bp repeat polymorphism in intron 4 of eNOS and numbers of circulating EPCs in presence of cardiovascular disease (CVD) risk factors in a group of healthy human volunteers. The study comprised of 45 healthy subjects (30–50 years). These subjects had various degrees of CVD risk but no history of CVD. The repeat polymorphism of eNOS was detected by polymerase chain reaction and EPC levels were analyzed by flow cytometry. We observed a good association between the intronic 4 mutant a/b genotype and the combined Framingham risk factor score in our subjects (χ2 = 3.2, P = 0.07). EPC numbers in subjects with mutant eNOS a/b genotype were also less than those observed in subjects with normal eNOS b/b genotype (P = 0.06). Interestingly, subjects with eNOS a/b genotype showed a significant inverse correlation between framingham risk score and EPC numbers (R = −0.57, P < 0.05). The study suggests that the presence of CVD risk factors in subjects with eNOS intron 4 polymorphism results in reduced number of circulating EPCs, which may significantly predispose them to CVD and aberrant endothelial repair.
KeywordsCardiovascular disease Endothelial nitric oxide synthase Endothelial progenitor cells Polymorphism
We are grateful to the Vice Chancellor, Gautam Buddha University for providing us the necessary facilities to perform the study. We are thankful to Dr. Nirupma Trehanpati, Institute of Liver and Biliary Sciences, New Delhi for her support in the flow cytometry experiments.
Compliance with Ethical Standards
Conflict of interest
All authors declare no conflict of interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 11.Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25:567–79.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Arora S, Das N, Srivastava K. Nitric oxide and eNOS gene in essential hypertension. Int J Collab Res Intern Med Public Health. 2009;1:56–71.Google Scholar
- 16.Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, Amiri P, Kouroshnia A, Bazzaz JT, Farahani-Shrhabi M, Larijani B, Amoli MM, et al. Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic application. Diabetes Res Clin Pract. 2011;91:348–52.CrossRefPubMedGoogle Scholar
- 19.Kumar TR, Uruno A, Sugawara A, Jayakumar K, Kartha CC. Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. Basic Res Cardiol. 2009;104:739–49.CrossRefPubMedGoogle Scholar
- 20.Kaur S, Harikrishnan VS, Radhakrishnan S, Shenoy SJ, Uruno A, Sugawara A, et al. Transfection of endothelial nitric oxide synthase gene improves angiogenic efficacy of endothelial progenitor cells in rabbits with hindlimb ischemia. J Clin Exp Cardiol. 2011;2:140. doi: 10.4172/2155-9880.1000140.CrossRefGoogle Scholar